Abstract: Compositions comprising aptamers, and methods of thereof as carrier molecules in cell-mediated immunotherapies, and activation of antigen-specific T-cell responses.

Abstract: Compositions comprising aptamers, and methods of thereof as carrier molecules in cell-mediated immunotherapies, and activation of antigen-specific T-cell responses.

Abstract: In an embodiment a reflector optical system includes a reflector body having a rotational symmetry about a longitudinal axis and including a first reflector optic portion having a substantially concave shape and a second reflector optic portion extending along the longitudinal axis, the first reflector optic portion facing the second reflector optic portion, wherein the first reflector optic portion includes a plurality of first reflective surfaces and the second reflector optic portion includes a plurality of second reflective surfaces in spaced light-receiving relation to the plurality of first reflective surfaces.

Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.

Abstract: An automotive solid-state headlamp includes a lamp body extending in a longitudinal direction, the lamp body having a rear base portion and a front portion and including a support member and a light-transmissive housing, a plurality of solid-state light sources arranged on the support member at the rear base portion of the lamp body, a drive circuitry electrically coupled to the light sources and arranged at the rear base portion of the lamp body and configured to operate the plurality of light sources when energized and reflector optics arranged at the front portion, wherein the solid-state light sources are configured to emit light towards the reflector optics, the reflector optics including a first reflector optic portion and a second reflector optic portion and wherein each of a plurality of first reflective surfaces disposed on the first reflector optic portion extend in an annular region around the longitudinal direction from the plurality of solid-state light sources towards the first reflector optic p

Abstract: The present invention relates to an aptamer not binding to the receptor-binding domain of the SARS-CoV-2 spike glycoprotein nor inhibiting the interaction of the receptor-binding domain (RED) of spike glycoprotein with angiotensin-converting enzyme II (ACE2) and/or comprising or consisting of a nucleotide sequence SEQ ID NO: 1, a composition comprising the aptamer, and the use of the aptamer in the detection of SARS-CoV-2 or diagnosis or treatment of a SARS-CoV-2 infection.

Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, preferably comprising or consisting of a nucleotide sequence SEQ ID NO: 4-6. The invention further relates to a composition comprising the aptamer, and the use of the aptamer as a medicament or a diagnostic reagent, particularly for use in the detection or diagnosing of a rejection of a renal allograft.

Abstract: In an embodiment an automotive solid-state headlamp includes a lamp body extending in a longitudinal direction, the lamp body having a rear base portion and a front portion and including a support member disposed in a light-transmissive housing, a plurality of solid-state light sources arranged on the support member at the rear base portion of the lamp body, and a drive circuitry electrically coupled to the light sources and arranged at the rear base portion of the lamp body and configured to operate the plurality of light sources when energized, wherein the plurality of light sources, when energized, are configured to cause the solid-state lamp to emit, through the light-transmissive housing (a) a luminous flux of at least 1500 lumens +/?10% when energized with a 13.2 Volt test voltage, or of at least 1750 lumens +/?10% when energized with a 28 Volt test voltage, or (b) a luminous flux of at least 1350 lumens +/?10% when energized with a 13.

Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.

Abstract: In an embodiment a reflector optical system includes a reflector body having a rotational symmetry about a longitudinal axis and including a first reflector optic portion having a substantially concave shape and a second reflector optic portion extending along the longitudinal axis, the first reflector optic portion facing the second reflector optic portion, wherein the first reflector optic portion includes a plurality of first reflective surfaces and the second reflector optic portion includes a plurality of second reflective surfaces in spaced light-receiving relation to the plurality of first reflective surfaces.

Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.

Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1 or a fragment thereof of at least 20 contiguous nucleotides of the nucleotide sequence SEQ ID NO: 2, wherein the aptamer comprises a polyethylene glycol (PEG) moiety conjugated to the 5? or the 3? end. The invention further relates to a composition comprising the aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly hormone refractory prostate tumours.

Abstract: The invention relates to a method of identifying or producing an aptamer, the method comprising the steps of: a) Providing a candidate mixture of nucleic acids; b) Contacting the candidate mixture with a target sample; c) Partitioning nucleic acids that bind to the target sample from those that do not bind; d) Amplifying the binding nucleic acids to produce a population of nucleic acids that bind the target sample; e) Single strand displacement of the amplified nucleic acids, f) optionally repeating the steps a) to e), thereby identifying or producing an aptamer, wherein the target sample provides one or more peptides and/or proteins in a denatured form.

Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.

Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a member of a ribonucleoprotein or spliceosomal complex such heterologous nuclear ribonucleoprotein U (hnRNP U).

Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.

Abstract: Methods are provided for selecting aptamers that are specific to a target of interest from amongst a library of potential aptamer sequences. Aptamers disclosed can be used to detect and/or characterize biological entities of interest, e.g. microvesicles and/or surface antigens. Further disclosed are biomarkers that can be used for diagnosing different disorders including different types of cancer.

Abstract: The invention relates to a method of identifying or producing an aptamer, and a reagent comprising a nucleic acid ligand capable of binding a target sample, wherein the nucleic acid ligand comprises at least one nucleobase modified to contain an azide-alkyne chemical group.

Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, a composition comprising an aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly solid tumors.

Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, a composition comprising an aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly solid tumours